Results 31 to 40 of about 169,027 (239)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

open access: yesFrontiers in Endocrinology, 2022
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 ...
B. Gallwitz
semanticscholar   +1 more source

GLP-1 receptor agonists for Parkinson's disease

open access: yesCochrane Database of Systematic Reviews, 2020
Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.
Caroline A, Mulvaney   +6 more
openaire   +3 more sources

When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]

open access: yes, 2016
Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier   +4 more
core   +2 more sources

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

open access: yesScientific Reports, 2021
Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases.
Sergei Y. Pechenov   +13 more
semanticscholar   +1 more source

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

open access: yesBMJ Open Diabetes Research & Care, 2019
Introduction This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM ...
Mukul Singhal   +5 more
doaj   +1 more source

The first successful desensitization protocol in exenatide allergy: a case report

open access: yesAllergy, Asthma & Clinical Immunology, 2023
Background Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes. To date, few immediate allergic reactions due to GLP-1 receptor agonists were reported.
Osman Ozan Yeğit   +6 more
doaj   +1 more source

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

open access: yes, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D.   +3 more
core   +2 more sources

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

open access: yes, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu   +4 more
core   +5 more sources

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects [PDF]

open access: yesFrontiers in Endocrinology, 2021
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and minimal side effects.
Xin Zhao   +8 more
openaire   +3 more sources

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

open access: yesPharmaceuticals, 2022
Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type
Ali Ismaeil   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy